Accessibility Menu

Clinuvel Pharmaceuticals(NASDAQ) CUVL

Market Cap$316.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-3%
5 Year-78%
1 Year-10%
1 Month-8%
$6.52
+3.82%
+0.24Today
Clinuvel Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 6.282026-09-03
Clinuvel Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.24%USD 6.772026-08-27
1 month-8.19%USD 6.842026-08-04
3 month-4.78%USD 6.602026-06-05
Year to date-25.94%USD 8.482025-12-30
1 year-10.45%USD 7.012025-09-03
3 year-46.91%USD 11.832023-09-01
5 year-78.32%USD 28.972021-09-03
Since inception-2.87%USD 6.472004-05-04

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$316.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.46

P/E Ratio

13.55

Dividend

$0.03

Beta (Volatility)

0.66 (Low)

Price

$6.52

Volume

79,283.835

Open

$6.29

Previous Close

$6.52

Daily Range

$6.10 - $6.73

52-Week Range

$5.95 - $8.92

Estimated Earnings Date

Feb 23, 2027

CUVL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for genetic, metabolic, and life-threatening disorders. The company is particularly known for its lead drug candidate, SCENESSE, which aims to prevent phototoxicity in patients with erythropoietic protoporphyria (EPP).

Products and Services
  • SCENESSE, a systemic photoprotective drug for EPP patients
  • CUV9900, an alpha-melanocyte stimulating hormone analogue
  • PRÉNUMBRA, a liquid injectable formulation of afamelanotide
Growth Outlook
  • Expansion into international markets enhances revenue potential
  • Ongoing development of NEURACTHEL targets neurological disorders
  • Increasing demand for photoprotective products supports market growth
Financial Highlights
  • Market capitalization stands at approximately $316.7 million
  • Recent stock price range between $5.95 and $8.92
  • Trailing twelve months dividend yield of 0.42%
Clinuvel Pharmaceuticals Ltd. operates in the healthcare sector, focusing on innovative solutions for patients with specific medical needs. The company's lead product, SCENESSE, has shown promise in treating EPP, a rare genetic disorder. The ongoing development of additional products, such as CUV9900 and PRÉNUMBRA, indicates a commitment to expanding its therapeutic offerings. The growth outlook for Clinuvel is bolstered by its strategic expansion into international markets, which may significantly enhance revenue opportunities. Furthermore, the development of NEURACTHEL aims to address neurological disorders, potentially broadening the company's market reach. The increasing demand for photoprotective products also positions Clinuvel favorably within the healthcare landscape. Financially, Clinuvel has a market capitalization of approximately $316.7 million, reflecting investor interest and confidence in its growth trajectory. The stock price has fluctuated between $5.95 and $8.92, indicating a stable trading range. Additionally, the company has maintained a trailing twelve months dividend yield of 0.42%, appealing to income-focused investors. Overall, Clinuvel Pharmaceuticals Ltd. presents a compelling opportunity for those interested in the biopharmaceutical sector.
AI Generated • Sep 4, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Philippe Jacques Wolgen, MD, MBA

Website

www.clinuvel.com

Headquarters

Melbourne, VIC 3000, AU

CUVL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

13.45%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

7.38%

Dividend Yield

0.52%

Payout Ratio

N/A

Stock Overview

Market Cap

$316.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.43M

Volume

79.28K

Avg. Volume

8.08K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Clinuvel Pharmaceuticals Performance Analysis

Clinuvel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 52,687,10410.5%
20242024-06-30USD 57,789,8619.7%
20252025-06-30USD 61,536,3236.5%
20262026-06-30USD 63,713,0893.5%
Clinuvel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.4035.8%
20242024-06-30USD 0.4615.2%
20252025-06-30USD 0.471.6%
20262026-06-30USD 0.45-2.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$316.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,713.41-0.00%
^DJIDJI
$53,418.31-0.00%
^IXICNASDAQ
$26,469.25-0.00%
BTCBitcoin
$79,600.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CUVL

What is the current price of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is trading at $6.52 per share.

What is the 52-week range for Clinuvel Pharmaceuticals?

Over the past 52 weeks, Clinuvel Pharmaceuticals has traded between $5.95 and $8.92.

How much debt does Clinuvel Pharmaceuticals have?

As of the most recent reporting period, Clinuvel Pharmaceuticals reported total debt of $1.34M.

How much cash does Clinuvel Pharmaceuticals have on hand?

Clinuvel Pharmaceuticals reported $14.16M in cash and cash equivalents in its most recent financial results.

What is Clinuvel Pharmaceuticals’s dividend yield?

Clinuvel Pharmaceuticals currently has a dividend yield of 0.52%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services